1. Previous Guidance on Myopia Control {#s1}
======================================

While eye care professionals have put forward views on how to slow myopia progression for centuries, the first evidence-based review to make clinical recommendations appears to have been in 2002, based on the only 10 randomized controlled trials to have been conducted at that time. This report concluded that bifocal spectacle lenses and soft contact lenses are not recommended for slowing the progression of myopia in children, nor is the routine use of atropine eye drops.[@i1552-5783-60-3-M1-b01] Since that time, more than 170 peer-reviewed articles on myopia control have been published, making it difficult for clinicians to keep abreast of the latest findings and how they should affect the optimum management of their patients. Few, if any, professional bodies have issued documented guidance on the treatment of myopia (in contrast to the correction of the refractive error). While eye care practitioners from across the globe seem concerned about the increasing levels of myopia in their practices, especially in Asia, and report relatively high levels of activity in controlling myopia, most still prescribe single-vision spectacles and contact lenses to their progressing myopes.[@i1552-5783-60-3-M1-b02] Hence, there is a need for evidence-based intervention strategies, informed by animal model and genetic studies, with agreement on how myopia should be defined, validated by well-designed and ethically applied clinical trials. The International Myopia Institute (IMI) reports represent the work of more than 85 multidisciplinary experts in the field, who set out to critically review, synthesize, and summarize the research evidence to date ([Table 1](#i1552-5783-60-3-M1-t01){ref-type="table"}), and serve to inform both clinical practice and future research.
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CREAM, the international Consortium for Refractive Error and Myopia.

2. The IMI Report Generation Process {#s2}
====================================

As highlighted in the accompanying editorial, the foundation of the IMI was an outcome of the World Health Organization--associated global scientific meeting on Myopia, held at the Brien Holden Vision Institute in Sydney, Australia, in 2015. As part of the IMI\'s mission to address identified key issues related to myopia, they approached a group of experts to produce two white papers in November 2015, one focused on Myopia Interventions (optical, pharmaceutical, and behavioral/environmental) and the other on Definitions and Classification of Myopia (high myopia, pathologic myopia, and myopic macular degeneration). An IMI steering and an advisory board were established also in November 2015 at the American Academy of Ophthalmology meeting in Las Vegas to oversee the process. A separate initiative at a similar time, led by James Wolffsohn and Nicola Logan of Aston University (Birmingham, UK), approached leading experts in the field to establish a steering committee to put together an evidence-based global consensus on myopia control, in particular to inform clinicians, based on the well-established approach taken by the Tear Film and Ocular Surface Society. The two groups agreed to bring the initiatives together at a meeting at The Association for Research in Vision and Ophthalmology (ARVO) in May 2016 in Seattle. It was agreed that Earl Smith and James Wolffsohn would chair the initiative supported by the IMI. Monica Jong from the Brien Holden Vision Institute facilitated the entire process. In March 2017, the new white papers to accompany the original two had been agreed on and potential chairs approached.

In developing this set of reports, the IMI has collaborated closely with the past and present organizers of The International Myopia Conference (IMC), an international event that has been in existence since 1964 and is now a biennial event ([Table 2](#i1552-5783-60-3-M1-t02){ref-type="table"}). The IMC is devoted to promoting all aspects of myopia research at the basic level through to translational research and clinical myopia research, thereby bringing together a wide range of disciplines. The attendance at the congress reflects the diversity of persons involved in myopia-related activities, including researchers, academics, practitioners, policy makers, industry representatives, and students. The IMC started more than 50 years ago; however, it was Sek Jin Chew in collaboration with Josh Wallman who was instrumental in reviving the conference in 1990. The site-hosting organization and organizing committee change for each meeting, thus ensuring diversity at many levels. Chew and Wallman re-established the IMC meetings, using local organizing committees beginning in 1990, adopting the numbering based on the original Myopia International Research Foundation sponsored meetings.

###### 
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  ------- -------------------------------------------------
  1st\*   New York, New York, United States (1964)
  2nd†    Yokohama, Japan (1978)
  3rd†    Copenhagen, The Netherlands (1980)
  2nd\*   San Francisco, California, United States (1984)
  3rd\*   Rome, Italy (1986)
  4th     Singapore (1990)
  5th     Toronto, Ontario, Canada (1994)
  6th     Hakone, Japan (1996)
  7th     Taipei, Taiwan (1998)
  8th     Boston, Massachusetts, United States (2000)
  9th     Hong Kong, Guangzhou (2002)
  10th    Cambridge, United Kingdom (2004)
  11th    Singapore (2006)
  12th    Cairns, Australia (2008)
  13th    Tübingen, Germany (2010)
  14th    Asilomar, California, United States (2013)
  ------- -------------------------------------------------

Organized by the Myopia International Research Foundation.

Independently organized by local organizing committees. (Not recognized by the Myopia International Research Foundation.)

Experts in the field (as identified by the IMI and IMC) were approached for expressions of interest to contribute to one of the reports of their choice. An inclusive approach was adopted, while limiting the number of participants from any one research group to ensure a balanced representation. Discussion between the chairs resulted in report selection for each individual, based on their expertise. The then IMI steering board (David Friedman, Mingguang He, Jonas Jost, Ohno-Matsui Kyoko, Kovin Naidoo \[chair\], Jason Nichols, Serge Resnikoff, Earl Smith, Hugh Taylor, Christine Wildsoet, James Wolffsohn, Tien Wong) and the chairs met at ARVO in May 2017 in Baltimore. The steering committee was responsible for developing the specific aims and mission, along with the strategy for these reports, and agreed on the topics, conflict of interest policy, chairs, and committee members. The chairs ([Table 3](#i1552-5783-60-3-M1-t03){ref-type="table"}) presented to a special session at the IMC in Birmingham, United Kingdom, in September 2017 and the report committee membership was expanded based on further interest and feedback. The report committees also met to finalize their paper\'s outline and to allocate the workload immediately after the meeting. Shortly after this meeting an agreement was put in place to publish all the reports in a special issue of *Investigative Ophthalmology & Visual Science* (*IOVS*).

###### 

Report Committees, Chairs, and Harmonizers

  **Report Subcommittee**                                             **Chair(s)**                **Harmonizer(s)**
  ------------------------------------------------------------------- --------------------------- --------------------------------
  Defining and Classifying Myopia                                     Ian Flitcroft               Earl Smith
  Experimental Models of Emmetropization and Myopia                   David Troilo & Earl Smith   Lyndon Jones
  Myopia Genetics                                                     Caroline Klaver             Earl Smith
  Interventions for Myopia Onset and Progression                      Christine Wildsoet          James Wolffsohn
  Clinical Myopia Control Trials and Instrumentation                  James Wolffsohn             Kovin Naidoo
  Industry Guidelines and Ethical Considerations for Myopia Control   Lyndon Jones                Serge Resnikoff & Kate Gifford
  Clinical Myopia Management Guidelines                               Kate Gifford                Padmaja Sankaridurg

By early 2018, the draft report was put together from the contributions of each committee, and authorship was determined on the basis of contribution. The draft reports were circulated to that committee to review as a whole, to ensure all issues were adequately addressed. In March 2018, the report drafts were circulated to all 88 members of the IMI committees (who came from 17 counties) for review by July. At ARVO in May 2018 the IMI steering committee received reports from each of the committee chairs. Reviewer comments were received by the report chairs and addressed one by one, as occurs in a traditional peer review of academic manuscripts, to ensure all views were considered. Experts in the field who work for industry were not excluded from the report committees owing to their valuable experience, but the review process outlined ensured no undue influence. The sponsors contributed to publication costs of the International Myopia Reports. The appointed harmonizer to each report (see [Table 3](#i1552-5783-60-3-M1-t03){ref-type="table"}) was then responsible for ensuring the reviewers\' comments had been adequately addressed, that overlap between the reports was minimized (with appropriate cross-referencing), and that the report styles were unified as much as possible.

The harmonizers had a meeting in August 2018 and subsequent email communication to resolve any issues arising. It was acknowledged that some areas of overlap would remain where aspects were approached from a different angle (such as crafting a clinical trial protocol as compared to clinical guidance). The imperative of promoting myopia control as an ethical imperative, due to the evidence-based risk of complications from higher levels of myopia and the availability of treatments with proven effectiveness (compared to the risk of complications from the treatment modality), was of particular note. Hence, the reports promote open communication with patients and their parents/guardians regarding the risk versus benefits, such that a fully informed, joint decision on treatment adoption can be made. Finalized harmonized reports were submitted for publication in *IOVS* in October 2018.

3. Background to the Need for Myopia Control {#s3}
============================================

3.1 Refractive Development {#s3a}
--------------------------

From birth, eye growth continues and refractive state normally undergoes a gradual shift toward emmetropia. In the first 6 months of life, human newborns typically have a variable, but low hyperopic, cycloplegic refractive error with mean of approximately +2.00 diopters (D) (±SD 2.75 D), which shows a normal distribution in the population.[@i1552-5783-60-3-M1-b03][@i1552-5783-60-3-M1-b04][@i1552-5783-60-3-M1-b05]--[@i1552-5783-60-3-M1-b06] Emmetropization over the subsequent 6 to 12 months of age leads to a reduction in hyperopia, and the normal distribution of refractive errors seen in neonates becomes more leptokurtic as the eye matures.[@i1552-5783-60-3-M1-b07] For the next several years, hyperopic refractive error will reduce slowly such that, by 5 to 7 years of age, most children will have a refractive error in the low hyperopic range (plano to +2.00 D).[@i1552-5783-60-3-M1-b03],[@i1552-5783-60-3-M1-b06],[@i1552-5783-60-3-M1-b08],[@i1552-5783-60-3-M1-b09] In populations with relatively low to modest education levels, refractive error is likely to endure at this level throughout the teenage and adult years.[@i1552-5783-60-3-M1-b10] In some individuals, for reasons not well understood, the refractive error will become myopic and is likely to progress for a period of time.

3.2 Myopia Onset {#s3b}
----------------

In children younger than 6 years the prevalence of myopia is low.[@i1552-5783-60-3-M1-b11][@i1552-5783-60-3-M1-b12][@i1552-5783-60-3-M1-b13][@i1552-5783-60-3-M1-b14][@i1552-5783-60-3-M1-b15][@i1552-5783-60-3-M1-b16][@i1552-5783-60-3-M1-b17][@i1552-5783-60-3-M1-b18]--[@i1552-5783-60-3-M1-b19] Even in East Asia and Singapore, where the prevalence of myopia is considered to be alarmingly high in young adults, most studies[@i1552-5783-60-3-M1-b12],[@i1552-5783-60-3-M1-b14],[@i1552-5783-60-3-M1-b15],[@i1552-5783-60-3-M1-b17],[@i1552-5783-60-3-M1-b20][@i1552-5783-60-3-M1-b21]--[@i1552-5783-60-3-M1-b22] show a prevalence rate of myopia in the pre--6-year-old age group to be less than 5%. In certain populations, myopia has been found in more than 5% of children younger than 6 years, although the prevalence rarely exceeds 10%.[@i1552-5783-60-3-M1-b11],[@i1552-5783-60-3-M1-b14],[@i1552-5783-60-3-M1-b23] Recent studies have reported that the incidence of myopia in this age group may be increasing. Fan et al.[@i1552-5783-60-3-M1-b23] report that the prevalence of myopia in Hong Kong preschoolers (mean age, 4.6 ± 0.9 years; range, 3--6 years) has increased significantly from 2.3% to 6.3% over 10 years.

The incidence of myopia increases dramatically in at-risk populations from approximately 6 years of age.[@i1552-5783-60-3-M1-b24] Previous studies have linked this change with the beginning of primary school education, and a link between the intensity of the education system and myopia onset has been determined.[@i1552-5783-60-3-M1-b10],[@i1552-5783-60-3-M1-b24],[@i1552-5783-60-3-M1-b25] The annual incidence of myopia onset is reasonably constant between the ages of approximately 7 and 15 years in Chinese populations and, by the age of 18 years, some 80% of the urban-based Han population in China is myopic, regardless of geographic locality.[@i1552-5783-60-3-M1-b17],[@i1552-5783-60-3-M1-b26][@i1552-5783-60-3-M1-b27]--[@i1552-5783-60-3-M1-b28] Singapore, Hong Kong, Taiwan, South Korea, and Japan show similar patterns, although incidence may be higher in Singapore, Taiwan, and Hong Kong at younger ages.[@i1552-5783-60-3-M1-b29][@i1552-5783-60-3-M1-b30][@i1552-5783-60-3-M1-b31][@i1552-5783-60-3-M1-b32][@i1552-5783-60-3-M1-b33][@i1552-5783-60-3-M1-b34][@i1552-5783-60-3-M1-b35][@i1552-5783-60-3-M1-b36]--[@i1552-5783-60-3-M1-b37] A systematic review and meta-analysis by Rudnicka et al.[@i1552-5783-60-3-M1-b37] has reported an increase of 23% in the prevalence of myopia over the last decade among East Asians.

In Western societies and countries other than those mentioned above, the incidence of myopia onset during childhood years, and thus the corresponding prevalence, is much lower.[@i1552-5783-60-3-M1-b37] Most of the myopia cases identified in one study in the United Kingdom was considered to be late onset (16 years or older).[@i1552-5783-60-3-M1-b38] [Figure 1](#i1552-5783-60-3-M1-f01){ref-type="fig"} illustrates the marked difference in prevalence between East Asian and white children from the meta-analysis of Rudnicka et al.[@i1552-5783-60-3-M1-b37] Of ethnicities reported in the meta-analysis, populations in south Asian, black populations in Africa, and Hispanics tended to have lower prevalence than Western white populations, with South-East Asians, black populations not in Africa, Middle Eastern/North African populations, Native Hawaiians, and American Indians showing higher prevalence than white populations, but still much lower than East Asians.[@i1552-5783-60-3-M1-b37]

![Modeled prevalence of myopia by age for East Asian and white children and teenagers from a systematic review and quantitative meta-analysis fitted to the year 2005. Graph created from data in [Table 3](#i1552-5783-60-3-M1-t03){ref-type="table"} of Rudnicka et al.[@i1552-5783-60-3-M1-b37]](i1552-5783-60-3-M1-f01){#i1552-5783-60-3-M1-f01}

Models, such as those reviewed in the accompanying IMI -- Defining and Classifying Myopia Report,[@i1552-5783-60-3-M1-b39] are likely to be efficient in predicting myopia onset, due in part at least, to identification of a process of myopic shift already under way. Since the predominant refractive error of young children is usually a low degree of hyperopia, and the consensus diagnostic criterion for myopia is −0.50 D, there is clearly a transition stage of refractive development for those destined to become myopic.[@i1552-5783-60-3-M1-b40] The onset of the myopic trajectory is relatively sudden compared to a subtle loss of hyperopia seen in those who remain emmetropic.[@i1552-5783-60-3-M1-b41][@i1552-5783-60-3-M1-b42]--[@i1552-5783-60-3-M1-b43] The myopic shift and acceleration of axial elongation that precedes the onset of myopia may be evident up to 4 years earlier and does not seem to vary between different ethnicities.[@i1552-5783-60-3-M1-b42] The high predictive value of the models of Zadnik et al.[@i1552-5783-60-3-M1-b44] and Zhang et al.[@i1552-5783-60-3-M1-b45] is therefore likely based on detection of values of refractive error and ocular biometry during the transition phase, which depart from those found in emmetropes of the same age.

3.3 Myopia Progression {#s3c}
----------------------

Progression of myopic refractive error tends to be studied less frequently than onset and prevalence in population-based studies. However, understanding the mechanisms and risk factors for both onset and progression, and the degree to which they vary, are important, so the phenomena are considered separately here. Longitudinal studies are optimal, but are resource intensive and consequently uncommon. Cross-sectional studies are useful when the mean refractive errors of myopes are segregated by age.

Donovan and colleagues[@i1552-5783-60-3-M1-b46] have conducted a meta-analysis of studies reporting myopia progression rates in children of Asian or European descent living in urban areas and corrected with single-vision spectacles. The analysis uses data from 20 studies, 14 intervention trials, and 6 longitudinal observation studies, to predict the progression of myopia and shows that among existing myopes, progression rate declines with increasing age. For example, according to the equation provided in the study of Donovan et al.,[@i1552-5783-60-3-M1-b46] progression declines from −1.12 D/y at age 7 years to −0.50 D/y at age 12 years among Asian children.

The progression rates presented by Donovan et al.[@i1552-5783-60-3-M1-b46] arise principally from control groups of intervention trials, which may not be representative of the general population. For example, parents of participants in such trials may have enrolled them because of concern that their children\'s myopia was progressing at a rapid rate when compared with their peers. Population-based and school-based studies tend to report somewhat slower progression. In a rural district in China with baseline data collected in 1998, a total of 4662 myopic (≤−0.5 D) children with a mean age of 9.8 years showed −0.84 D progression during 28.5 months, an average annual progression rate of −0.35 D.[@i1552-5783-60-3-M1-b47] The timing of the study and rural habitation of this population may explain some of the difference in myopic progression rate compared with the meta-data reported by Donovan et al.[@i1552-5783-60-3-M1-b46] The average annual progression rate for a sample including more than 7500 myopic children aged 5 to 16 (mean, 9.3) years in Hong Kong was reported at −0.63 D.[@i1552-5783-60-3-M1-b12] Chua et al.[@i1552-5783-60-3-M1-b48] have plotted annual changes in refractive error for 928 myopic Singaporean children of mixed ethnicity from age 7 to 11 years, stratified by age of myopia onset. Mean progression rate at a given age is remarkably consistent across the groups, irrespective of age of onset. These mean progression rates are slightly slower than those reported by Donovan et al.[@i1552-5783-60-3-M1-b46] ([Fig. 2](#i1552-5783-60-3-M1-f02){ref-type="fig"}).

![Refractive shift among myopic children by age. Data from Donovan et al.[@i1552-5783-60-3-M1-b46] were digitized by using ImageJ (<http://imagej.nih.gov/ij/>; provided in the public domain by the National Institutes of Health, Bethesda, MD, USA) and replotted, and the best fit line for Asians was taken from the equation provided in their article. Data for Chua et al.[@i1552-5783-60-3-M1-b48] were obtained by averaging progression rates for given ages from their Figure 2.](i1552-5783-60-3-M1-f02){#i1552-5783-60-3-M1-f02}

In a large population-based study in Yongchuan District of Chongqing City, Western China, children aged 6 to 15 years in 2006--2007 have been followed up for an average of 5.2 years.[@i1552-5783-60-3-M1-b49] The authors report mean progression of −3.56 D (average, −0.68 D/y) among myopes (≤−0.50 D) during this time. While presentation of the data does not allow direct comparison, these progression rates may well be closer to those reported by Donovan et al.[@i1552-5783-60-3-M1-b46] Kim and colleagues[@i1552-5783-60-3-M1-b50] have retrospectively analyzed refractive error progression among a population of 221 myopic South Korean children aged 3 to 9 years for an average of 11.2 years. While this was a hospital-based study, and therefore not necessarily representative of the population at large, the progression rate of approximately −0.50 D/y between the ages of 7 and 13 years was surprisingly modest. Hsu and coworkers[@i1552-5783-60-3-M1-b51] have reviewed a population-based cohort in Taiwan of 3256 myopic children, of average age 7.5 years, after 1 year and noted average progression in the group of only −0.42 D, well below that predicted by Donovan et al.[@i1552-5783-60-3-M1-b46] Some of these children were being treated with cycloplegics to slow myopia progression and all had been exposed to a large-scale eye care education program, which may explain the lower progression rate. Most recently, Wu et al.[@i1552-5783-60-3-M1-b52] have found annual progression of −0.79 D among a school-based control population of 89 myopes aged 6 and 7 years in Taiwan. This is also less than predicted by Donovan et al.,[@i1552-5783-60-3-M1-b46] but it should be noted that those in the sample population receiving myopia treatment were excluded from the analysis.

Further details of likely progression can be obtained from centile progression curves. Chen et al.[@i1552-5783-60-3-M1-b53] have constructed reference age-specific centile curves of refraction from cross-sectional population-based data from the Guangzhou Refractive Error Study in Children. However, apparent progression among the myopes between ages of 7 and 12 years is observed to be only approximately −0.5 to −0.6 D/y, comparatively constant across ages, and less again than that of Donovan et al.,[@i1552-5783-60-3-M1-b46] particularly at a younger age. The implications of these differences are not clear. Tideman et al.[@i1552-5783-60-3-M1-b54] have also produced age-specific centile curves for axial length. The relative functionality of these curves compared to those for refractive error is yet to be determined.

Based on the above literature review, greater myopia progression rates are expected at younger ages (i.e., −0.50 to −1.00 D/y for 6- to 9-year-olds) than at older ages (i.e., −0.35 to −0.75 D for those older than 10 years).

3.4 High Myopia {#s3d}
---------------

One of the major ethical challenges for practitioners is accurate identification of those at risk of becoming highly myopic or, at the very least, of those whose myopia is progressing at an unacceptably fast rate. Few analyses are available on this topic, but the breakdown by Chua et al.[@i1552-5783-60-3-M1-b48] probably represents the most comprehensive data available. They have found age of onset of myopia to be the strongest predictor of high myopia among Singaporean children.[@i1552-5783-60-3-M1-b48] As expected, duration of myopia progression was also important in predicting high myopia. For children with high myopia at age 11 years, there was an 87% chance that the child became myopic at 7 years of age or younger or had a duration of myopia progression of 4 years or more. Reports from other countries (Denmark, Argentina, United Kingdom) reliably reproduce this observation.[@i1552-5783-60-3-M1-b55][@i1552-5783-60-3-M1-b56]--[@i1552-5783-60-3-M1-b57] However, in contrast to the report by Chua and colleagues,[@i1552-5783-60-3-M1-b48] Williams et al.[@i1552-5783-60-3-M1-b57] have found that age of onset only accounts for a modest proportion (approximately 15%) of the variance in severity of myopia.

3.5 Adult-Onset Myopia and Progression {#s3e}
--------------------------------------

Most of the myopia cases in one study in Britain were considered to be late onset (16 years or older).[@i1552-5783-60-3-M1-b38] Although myopia onset past the adolescent stage of life is of clinical interest and has shown an association with environmental factors,[@i1552-5783-60-3-M1-b58] eye care practitioners are generally more concerned from an ethical standpoint with identifying patients at risk for development of higher degrees of myopia, which typically involves juvenile-onset myopia and its associated potential to progress to sight-threatening pathology.

The prevailing perception is that myopia stabilizes in the late teenage years.[@i1552-5783-60-3-M1-b41] Certainly, annual progression in most myopic patients slows with time and for many myopes whose condition has progressed through the teenage years, myopia will stabilize before they reach 20 years of age. However, there are patients whose myopia will continue to progress through adult years.[@i1552-5783-60-3-M1-b58][@i1552-5783-60-3-M1-b59]--[@i1552-5783-60-3-M1-b60] These patients include those doing intense near work, especially students, and those who have higher degrees of myopia. Continued assessment of refraction and initiation of treatment in patients showing continued progression are warranted. Higher levels of myopia will result from continued progression through adulthood, placing these individuals at higher risk for development of myopia-associated pathologies.

3.6 Genetic and Environmental Risk {#s3f}
----------------------------------

Risk factors for myopia onset have been identified and included in a number of multivariate models, although to our knowledge there is currently no comprehensive clinical model that provides good predictive value, aside from those using refractive or biometric information. McMonnies[@i1552-5783-60-3-M1-b61] has provided a review of risk factors for onset and progression of myopia and produced a comprehensive table of those factors and how they may influence the prognosis and treatment decisions for individual patients. However, he also notes that the lack of clinical data on the topic of risk "undermines the confidence with which individual prognoses and clinical decisions about interventions can be made."

### 3.6.1 Myopia Onset {#s3f1}

#### Genetics and Personal Characteristics {#s3f1a}

Heritability statistics can be used to estimate the proportion of variation in a phenotypic trait of a population that is due to genetics, and further details can be found in the accompanying IMI -- Myopia Genetics Report.[@i1552-5783-60-3-M1-b62] Heritability estimates for myopia vary from 0.11 to 0.98, the latter higher value being found among a highly specific group of Finnish female twins aged 28 to 29 years.[@i1552-5783-60-3-M1-b63],[@i1552-5783-60-3-M1-b64] A meta-analysis[@i1552-5783-60-3-M1-b65] places heritability at 0.71 for refractive error, which would suggest that the majority of influence is from genetics rather than environment.

Genome-wide association studies (GWAS)[@i1552-5783-60-3-M1-b66] have demonstrated complex inheritance of refractive error traits, with identification of more than 150 gene loci associated with myopia and good correlation between studies. However, the identified loci explain a meagre percentage of the variance in refractive error.[@i1552-5783-60-3-M1-b67] For example, a genetic risk score (GRS) has estimated that these loci explain only 0.6% and 2.3% of the variance in refractive error at ages 7 and 15 years, respectively.[@i1552-5783-60-3-M1-b68] The difference between heritability from twin studies and GWAS is known as "missing heritability" or the "heritability gap" and is a well-known characteristic of other phenotypes and diseases.[@i1552-5783-60-3-M1-b66]

While the nature versus nurture debate continues in relation to myopia development, recognition of the importance of gene-environment interactions in phenotypic expression has been a significant step forward. Fan et al.[@i1552-5783-60-3-M1-b68] have tested for evidence of interactions between near work or time spent outdoors and 39 previously identified loci from GWAS in refractive development in a pediatric cohort. Five variants have shown apparent interaction with near work, while neither variant nor GRS effects were altered with time outdoors.[@i1552-5783-60-3-M1-b68]

The most useful clinical indicator for genetic risk short of genetic testing is parental history of myopia. Older studies demonstrating this association have been reviewed by Goss and Jackson.[@i1552-5783-60-3-M1-b69] Studies since that time show significant association between number of myopic parents and incident myopia, as summarized in a recent meta-analysis.[@i1552-5783-60-3-M1-b70] Odds ratios (ORs) ranging from 1.44 to 2.96 for having a myopic child compared to not having a myopic child were calculated, depending on the number of myopic parents and adjustment for bias and missing studies.[@i1552-5783-60-3-M1-b70] More recent studies confirm the connection.[@i1552-5783-60-3-M1-b27],[@i1552-5783-60-3-M1-b71][@i1552-5783-60-3-M1-b72][@i1552-5783-60-3-M1-b73][@i1552-5783-60-3-M1-b74][@i1552-5783-60-3-M1-b75]--[@i1552-5783-60-3-M1-b76] Parental myopia has also been found to interact with other risk factors. In one study of 1770 grade-7 Chinese students, those with close reading distances and two myopic parents have a 26-fold higher odds for prevalent myopia than children with reading distances of greater than 20 cm and no myopic parents.[@i1552-5783-60-3-M1-b77],[@i1552-5783-60-3-M1-b78] Also, unsurprisingly, parental myopia correlates with certain ocular components, particularly axial length.[@i1552-5783-60-3-M1-b79],[@i1552-5783-60-3-M1-b80]

There are some further considerations around parental myopia as a risk factor. The additive genetic portion of phenotypic variance is smaller in younger families, reflecting the trend for increasing environmental influences.[@i1552-5783-60-3-M1-b81] The odds of a child with two myopic parents becoming myopic is thus different to the odds of a myopic child having two myopic parents. In part, this stems from increased myopia prevalence, meaning that there will likely be more children with myopia than there are parents with myopia.[@i1552-5783-60-3-M1-b43] Number of myopic parents is a relatively gross instrument and a knowledge of degree of myopia in family members may be a more useful factor for predicting progression.[@i1552-5783-60-3-M1-b61],[@i1552-5783-60-3-M1-b82] Because of these factors, the sensitivity of number of myopic parents in predicting childhood myopia is correspondingly low.[@i1552-5783-60-3-M1-b82],[@i1552-5783-60-3-M1-b83]

Rudnicka et al.[@i1552-5783-60-3-M1-b37] also have found that sex differences emerge in myopia prevalence at approximately 9 years of age in whites and East Asians. By 18 years of age, white females have 2.0 (95% confidence interval \[CI\], 1.4--2.9) times the odds of myopia as white males, and East Asian females have 2.3 (95% CI, 2.0--2.6) times the odds of myopia as East Asian males. Others[@i1552-5783-60-3-M1-b27],[@i1552-5783-60-3-M1-b71],[@i1552-5783-60-3-M1-b73] since have confirmed the propensity for greater myopia prevalence among females. The extent to which this influence is environmental as opposed to genetic has yet to be determined.

#### Environment {#s3f1b}

Ramamurthy and colleagues[@i1552-5783-60-3-M1-b84] have reviewed the large number of environmental risk factors for myopia. Two key environmental influences upon myopia development are time spent outdoors and amount of near work. The reason time spent outdoors is protective against myopia development remains unexplained. Although there is some evidence from animal studies showing that high light levels or chromaticity might be the critical factor,[@i1552-5783-60-3-M1-b84] Flitcroft[@i1552-5783-60-3-M1-b85] and Ngo et al.[@i1552-5783-60-3-M1-b86] present a counter-argument as to why the dioptric field, perhaps in an interaction with the high light level, is central to protection from time spent outdoors. Xiong et al.[@i1552-5783-60-3-M1-b87] have reviewed multiple studies and suggest a clear connection between time spent outdoors and myopia onset. However, differentiation between consequence and causality can only be shown in prospective randomized studies. As spending time outdoors is an intervention to prevent or delay myopia development, detailed description of this risk factor for myopia onset is presented in the accompanying IMI -- Interventions for Controlling Myopia Onset and Progression Report.[@i1552-5783-60-3-M1-b88]

Despite some indications that near work may not be directly related to myopia, more recent evidence suggests a clear link.[@i1552-5783-60-3-M1-b89] "Near work" has been defined and measured in a multitude of ways across different studies (e.g., education level, duration of continuous study time, time spent reading books for pleasure, number of books read per week, time spent on reading and close work, time spent indoors studying, closer working distance, short reading distance, distance from near work, font size, and screen-viewing activities) and is, by its nature, difficult to quantify. Nonetheless, in a systematic review and meta-analysis, Huang et al.[@i1552-5783-60-3-M1-b89] have found more time spent on near-work activities is associated with higher odds of myopia, increasing by 2% for every additional diopter-hour of near work per week. Multiple subsequent articles not included in this meta-analysis also confirm the association of some index of near work with development and progression of myopia, often independently from time spent outdoors in multivariate analyses.[@i1552-5783-60-3-M1-b27],[@i1552-5783-60-3-M1-b51],[@i1552-5783-60-3-M1-b52],[@i1552-5783-60-3-M1-b72],[@i1552-5783-60-3-M1-b75],[@i1552-5783-60-3-M1-b76],[@i1552-5783-60-3-M1-b78],[@i1552-5783-60-3-M1-b90][@i1552-5783-60-3-M1-b91]--[@i1552-5783-60-3-M1-b92] French and coworkers[@i1552-5783-60-3-M1-b93] have presented data that illustrate a strong interaction between the effect of time spent outdoors and near work. In children with baseline mean age of 6 years, those who spend low amounts of time outdoors and perform high levels of near work have dramatically increased odds of incident myopia by age 12 years (OR, 15.9; 95% CI, 3.5--73.4) as compared with those who spend high amounts of time outdoors and low amount of time involved in near work.

Both country and location of residency (urban versus rural) of an individual are associated with the likelihood of myopia. Rose et al.[@i1552-5783-60-3-M1-b94] have found that the prevalence of myopia in 6- to 7-year-old children of Chinese ethnicity is significantly lower in Sydney, Australia (3.3%) than Singapore (29.1%). In their large meta-analysis of childhood myopia prevalence from population-based surveys, Rudnicka et al.[@i1552-5783-60-3-M1-b37] have shown striking differences in prevalence among school-aged children of Eastern Chinese ancestry, based on their country of residence ([Fig. 3](#i1552-5783-60-3-M1-f03){ref-type="fig"}). Among South Asian children living in Australia, England, or Singapore, myopia was five times as likely compared to those living in India or Nepal. There was no apparent difference in prevalence of myopia among white children in studies from Europe, United States, and Oceania.

![Modeled prevalence of myopia by age for East Asians by selected country of residence from a systematic review and quantitative meta-analysis adjusted to the year 2005 (except for Mongolia, which is 2003). Graph created from data in Table 4 of Rudnicka et al.[@i1552-5783-60-3-M1-b37]](i1552-5783-60-3-M1-f03){#i1552-5783-60-3-M1-f03}

The authors also determined that children from urban environments have 2.6 (95% CI, 1.8--3.9) times higher odds of myopia than those from rural environments.[@i1552-5783-60-3-M1-b37] Consistent with this finding, population density, home size, and housing type are also significantly associated with refractive error and axial length.[@i1552-5783-60-3-M1-b95],[@i1552-5783-60-3-M1-b96] The mediating factors for all of the environmental effects are likely to be a combination of education, near work, and time spent outdoors.

Physical attributes (height, weight, and body mass index),[@i1552-5783-60-3-M1-b29],[@i1552-5783-60-3-M1-b97],[@i1552-5783-60-3-M1-b98] prenatal history,[@i1552-5783-60-3-M1-b99] birth season,[@i1552-5783-60-3-M1-b100],[@i1552-5783-60-3-M1-b101] intelligence,[@i1552-5783-60-3-M1-b102],[@i1552-5783-60-3-M1-b103] and socioeconomic status[@i1552-5783-60-3-M1-b27],[@i1552-5783-60-3-M1-b104],[@i1552-5783-60-3-M1-b105] have all been linked to the likelihood of myopia, with varying strengths of association.

#### Binocular Vision {#s3f1c}

It has long been postulated that myopia onset and progression may be related to dysfunctional accommodation and convergence.[@i1552-5783-60-3-M1-b106] An elevated accommodation-convergence/accommodation (AC/A) ratio has been observed before the onset of myopia.[@i1552-5783-60-3-M1-b44],[@i1552-5783-60-3-M1-b107] In a large, ethnically diverse group of children followed up for an extensive period of time, Mutti and colleagues[@i1552-5783-60-3-M1-b108] have found the AC/A ratios of those who become myopic begin to increase approximately 4 years before myopia diagnosis, continue increasing until diagnosis, and then plateau at a level higher than those who remain emmetropic.

Another feature of accommodation that has been observed is that measured lag of accommodation is larger among myopes than nonmyopes.[@i1552-5783-60-3-M1-b109],[@i1552-5783-60-3-M1-b110] It was thought that the presence of lag before onset may produce hyperopic retinal defocus, stimulating myopia onset. However, this effect only appears at the time of onset, not before, and does not seem to impact progression.[@i1552-5783-60-3-M1-b108],[@i1552-5783-60-3-M1-b111] An aspect of accommodative lag worthy of mention is that spurious measurement of accommodative error is well documented.[@i1552-5783-60-3-M1-b112][@i1552-5783-60-3-M1-b113]--[@i1552-5783-60-3-M1-b114] So-called lag may be substantially a function of the measurement technique, where depth of focus and increasing negative spherical aberration with accommodation and developing myopia are not taken into account.

The shift in refraction (in terms of a reduction in hyperopia) observed in those who will become myopic compared to those who remain emmetropic begins several years before diagnosis. Changes to the AC/A ratio merely seem to parallel such changes. Accommodative lag does not seem to appear until myopia onset.[@i1552-5783-60-3-M1-b115] Thus, while binocular vision attributes are an interesting research adjacency in the onset and development of myopia, from our current knowledge they do not seem to add any additional benefit in risk assessment over refraction and biometric parameters, genetics, or environmental effects.

### 3.6.2 Myopia Progression {#s3f2}

Compared with onset, there is a lower volume of literature describing risk of progression for existing myopes other than age and initial refractive error. Some studies have looked at group progression, including emmetropes and hyperopes as well as myopes in their analyses, which does not allow specific interpretation regarding progression among myopes.

#### Genetics and Personal Characteristics {#s3f2a}

Donovan et al.[@i1552-5783-60-3-M1-b46] report that myopia in European children progresses more slowly on average than in Asians (−0.55 D/y and −0.82 D/y, respectively, at mean age of 9.3 years), although age-specific progression data by baseline age for Europeans in their analysis are derived from a single article. For studies conducted in somewhat homogeneous Western societies, the analysis of Mutti et al.[@i1552-5783-60-3-M1-b42] supports the ethnic differences in progression rates found in the study by Donovan and colleagues,[@i1552-5783-60-3-M1-b46] although French et al.[@i1552-5783-60-3-M1-b116] did not establish significance of an ethnicity effect. Gwiazda and colleagues[@i1552-5783-60-3-M1-b117] have looked at risk factors for high myopia, which can be considered a corollary of fast progression. Reporting on an ethnically diverse population of children aged 6 to 11 years with initial myopia between −4.50 and −1.25 D at four sites within the United States, they did not find an effect of ethnicity on progression rates. Environment is also likely to play a role in myopic progression rates, which may be inferred from higher degrees of myopia among Asian children living in Asia compared to those living in Western societies; however, a thorough review of differences in progression rates between ethnically similar populations in different environments does not seem to have been undertaken.

In their study, Gwiazda et al.[@i1552-5783-60-3-M1-b117] found that the number of myopic parents is a risk factor for high myopia. Some studies support the proposition that parental myopia is associated with faster progression rates, where others do not.[@i1552-5783-60-3-M1-b91],[@i1552-5783-60-3-M1-b118],[@i1552-5783-60-3-M1-b119]

Females show faster progression than males according to Donovan et al.[@i1552-5783-60-3-M1-b46] (−0.80 D/y and −0.71 D/y, respectively, at mean age 8.8 years) and Zhou et al.[@i1552-5783-60-3-M1-b49] (OR, 1.45; 95% CI, 1.12--1.84). However, such a difference is not evident in the study of Gwiazda et al.[@i1552-5783-60-3-M1-b117]

#### Environment {#s3f2b}

In their meta-analysis, Xiong et al.[@i1552-5783-60-3-M1-b87] report that outdoor time is not effective in slowing progression in eyes that are already myopic. However, a more recent prospective study[@i1552-5783-60-3-M1-b52] suggests that outdoor time does have a protective effect on rate of progression. Subsequent cohort studies[@i1552-5783-60-3-M1-b51],[@i1552-5783-60-3-M1-b74],[@i1552-5783-60-3-M1-b118],[@i1552-5783-60-3-M1-b120] yield mixed results. Support for the protective effect of time spent outdoors on myopia progression may be inferred from numerous studies that have found a seasonal variation in myopia progression;[@i1552-5783-60-3-M1-b121][@i1552-5783-60-3-M1-b122]--[@i1552-5783-60-3-M1-b123] see the accompanying Interventions for Controlling Myopia Onset and Progression Report.[@i1552-5783-60-3-M1-b88]

Many of the same environmental factors that are linked to the incidence or prevalence of myopia are also related to progression. Multiple articles link near work, with various descriptors of activity, to myopia progression.[@i1552-5783-60-3-M1-b51],[@i1552-5783-60-3-M1-b52],[@i1552-5783-60-3-M1-b72],[@i1552-5783-60-3-M1-b74],[@i1552-5783-60-3-M1-b91],[@i1552-5783-60-3-M1-b119],[@i1552-5783-60-3-M1-b120] Other associations include urbanization and increasing family income.[@i1552-5783-60-3-M1-b90],[@i1552-5783-60-3-M1-b91]

#### Binocular Vision {#s3f2c}

Two studies that have considered binocular vision effects as part of the treatment protocol (esophoria or low lag of accommodation) have had good success, suggesting that some aspect of binocular function may be a risk factor for progression.[@i1552-5783-60-3-M1-b124],[@i1552-5783-60-3-M1-b125]

3.7 Summary of Findings on Risk Factors {#s3g}
---------------------------------------

The observations reported above present an unambiguous message. The younger the age of onset of myopia, the greater the likelihood that a child will experience progression to vision-threatening levels of myopia. Practitioners and parents should be active in addressing both myopia onset and progression at as young an age as possible. No formal procedures have been identified that recognize those at risk of myopia onset before the triggering of the steady progression in refractive error that ultimately leads to myopia diagnosis. However, it is clear, for example, that Chinese children living in urban regions of Asia, who are immersed in an intensive education environment and have two myopic parents, have a much greater risk for onset and development of significant myopia than a Caucasian living in a rural environment in Australia with no myopic parents. Not all children who are young at myopia onset will experience progression to high myopia, but age of onset is the current best determinant for identifying children at risk of progression. While noting the risk of high myopia is greatest in those with early onset, practitioners should also be cognizant that the condition of some individuals with later onset (say 11 years or older) may also progress to higher degrees of myopia, where the rate of progression is high. Practitioners should be vigilant in identifying and treating those at risk of rapid progression, regardless of age of onset.

4. Subcommittees and Their Report Focus and Advancements {#s4}
========================================================

4.1 IMI -- Defining and Classifying Myopia Report[@i1552-5783-60-3-M1-b39] {#s4a}
--------------------------------------------------------------------------

Myopia has been the topic of scientific study for more than 400 years, but it is only more recently that it has been recognized as a serious public health issue, owing to its being a significant cause of visual loss and a risk factor for a range of pathologic ocular conditions. Its prevalence is increasing on a global basis and has reached epidemic levels in much of Asia. Myopia has been defined in a wide variety of ways in the past, such as based on its assumed etiology, age of onset, progression rate, degree of myopia (in diopters), and structural complications. This has led to a confusing accumulation of terms. Hence this subcommittee\'s aim was to provide a standardized set of terminology, definitions, and thresholds of myopia and its main ocular complications. A critical review of current terminology and choice of myopia thresholds was undertaken to ensure that the proposed standards are appropriate for clinical research purposes, relevant to the underlying biology of myopia, acceptable to researchers in the field, and useful for developing health policy. It is recommended that the many descriptive terms of myopia be consolidated into the following descriptive categories:

> Myopia: A refractive error in which rays of light entering the eye parallel to the optic axis are brought to a focus in front of the retina when ocular accommodation is relaxed. This usually results from the eyeball being too long from front to back, but can be caused by an overly curved cornea, a lens with increased optical power, or both. It is also called nearsightedness.

With qualifying terms:

> Axial Myopia: A myopic refractive state that can be attributed to excessive axial elongation.

> Refractive Myopia: A myopic refractive state that can be attributed to changes in the structure or location of the image-forming structures of the eye (i.e., the cornea and lens).

> Secondary Myopia: A myopic refractive state for which a single, specific cause (e.g., drug, corneal disease, or systemic clinical syndrome) can be identified that is not a recognized population risk factor for myopia development.

It was also recommended that in quantitative contexts, myopia should always be treated as a negative value and that mathematical comparison symbols be used in their strict mathematical sense.

To provide a framework for research into myopia prevention, the condition of "premyopia" is defined.

> Premyopia: A refractive state of an eye of ≤+0.75 D and \>−0.50 D in children where a combination of baseline refraction, age, and other quantifiable risk factors provides a sufficient likelihood of the future development of myopia to merit preventative interventions.

As a quantitative trait it is recommended that myopia be divided into myopia (i.e., all myopia), low myopia, and high myopia as based on the current consensus of publications:

> Myopia: A condition in which the spherical equivalent refractive error of an eye is ≤−0.5 D when ocular accommodation is relaxed.

> Low Myopia: A condition in which the spherical equivalent refractive error of an eye is ≤−0.5 D and \>−6.00 D when ocular accommodation is relaxed.

> High Myopia: A condition in which the spherical equivalent refractive error of an eye is ≤−6.00 D when ocular accommodation is relaxed.

Although even low levels of myopia are associated with an increased risk of developing pathologic conditions such as myopia maculopathy and having a retinal detachment, "pathologic myopia" is proposed as the categorical term for the adverse, structural complications of myopia.

> Pathological Myopia: Excessive axial elongation associated with myopia that leads to structural changes in the posterior segment of the eye (including posterior staphyloma, myopic maculopathy, and high myopia--associated optic neuropathy) and that can lead to loss of best-corrected visual acuity.

A clinical classification is also proposed to encompass the scope of such structural complications.

4.2 IMI -- Experimental Models of Emmetropization and Myopia Report[@i1552-5783-60-3-M1-b126] {#s4b}
---------------------------------------------------------------------------------------------

Much of our current understanding of characteristics and mechanisms of postnatal eye growth and the development of myopia has come from detailed experimental studies using animal models. These models use a wide range of species, from primates to invertebrates, and include macaque and marmoset monkeys, tree shrews, guinea pigs, mice, chickens, fish, and squids. Considering that these phylogenetically wide-ranging species all possess visually guided eye growth despite differences in ecology, ocular anatomy, visual function, and visual acuity, this supports the hypothesis that visually guided eye growth is an evolutionarily conserved process found in camera-type eyes. Each species provides unique experimental advantages to study the mechanisms of visually guided eye growth and the key signalling pathways that regulate refractive eye development across species; however, anatomic and physiological differences must be taken into account when interpreting and translating results to humans.

The report summarizes the anatomic similarities and differences between the eyes of the principal experimental species used for studies of emmetropization and myopia. Surveying more than 800 published reports on the changes in eye growth and refractive state in response to experimental manipulations of visual conditions, the report offers a summary of the evidence supporting the role of vision in eye development and the mechanisms that underlie the visual regulation of eye growth and emmetropization development. Also discussed are the key operating characteristics of experimental emmetropization to experimentally imposed retinal defocus including local retinal mechanisms controlling regional eye growth, the spatial and temporal integration of visual signals, the impact of simultaneous competing defocus signals, the relationships of various ocular circadian rhythms to induced changes in eye growth, and the critical periods for visual experience--invoked myopia. Studies of the characteristics of the visual signals affecting eye growth are also reviewed and discussed, including the intensity of ambient illumination, the spectral composition of light, longitudinal chromatic aberration, higher-order monochromatic aberrations, and astigmatism. The report reviews the biochemistry of refractive error development, including the roles of various retinal neurotransmitters, neuromodulators, and growth promotors such as dopamine, vasoactive intestinal peptide, melanopsin, glucagon, and insulin, and nitric oxide. Pharmacologic studies of the mechanisms of emmetropization and myopia are discussed including the effects of cholinergic, GABAergic, and adenosine antagonistic drugs and drugs affecting nitric oxide and neuropeptides. Finally, the article reviews the molecular biology of gene expression in the eye and retina and possible gene-environment interactions.

The report reviews and summarizes several confirmed findings from animal models that have provided important proofs of concept that helped to transform treatment strategies for myopia control. These findings include the eye\'s ability to detect the sign of retinal defocus and undergo compensatory growth, the local retinal control of eye growth, regulatory changes in choroidal thickness, and the identification of biochemical signal cascades regulating postnatal eye growth and refractive state. Experimental animal models continue to provide new insights into the cellular and molecular mechanisms of eye growth control, including the identification of potential new targets for drug development and future treatments needed to stem the increasing prevalence of myopia and the vision-threatening conditions associated with this disease.

4.3 IMI -- Myopia Genetics Report[@i1552-5783-60-3-M1-b62] {#s4c}
----------------------------------------------------------

Like other complex traits, myopia has benefitted enormously from the dramatic improvements in DNA technologies and significant reduction in costs for genotyping during the last decade. The IMI -- Myopia Genetics Report summarizes the developments in gene identification for refractive error and myopia, and addresses their implications for molecular pathways. An extensive literature search identified almost 200 genetic loci that have been reported for refractive error, myopia, or axial length, and many overlap between these endophenotypes. Risk variants have mostly been identified outside the protein coding regions, and by themselves carry a low risk. Nevertheless, totalling all genetic risk variants in a polygenic risk score shows that those with a high genetic load are \>40 times more likely to become myopic, and high myopes and high hyperopes can be separated by their genetic score. The most significant contribution of the current gene dissection is the insights into the molecular machinery underlying eye growth. Functions of the annotated genes include retinal cell physiology, light processing, glutamate receptor signalling, extracellular matrix modulation, anterior segment morphology, but also posttranscriptional regulation indicating control of gene expression at the RNA level. In silico and in vitro experiments have shown that all cell types in the retina, but also RPE, vascular bed, and connective tissue are sites of gene expression. This implies that the retinal signalling cascade responding to a visual trigger and leading to eye growth involves a complex network of molecules from many different cells and tissues. Another lesson learned from the genetic studies is that most genes are not eye specific and have a plethora of effects outside of the eye. A fair number of genes for common myopia are involved in a wide range of syndromes, including neurodegenerative and connective tissue disorders. How this broad spectrum of gene functions leads to scleral remodelling and an increase of axial length remains intriguing. Addressing this "black box" requires taking myopia molecular genetics to the next level: to explore new high-throughput, wide coverage genotyping assays; determine the protein function and the elements that regulate gene expression; investigate how DNA, proteins, and the environment interact to determine eye size; and create possibilities for storage and reuse of massive genomic data. The forecast of understanding and solving myopia makes these challenges worth taking.

4.4 IMI -- Interventions for Controlling Myopia Onset and Progression Report[@i1552-5783-60-3-M1-b88] {#s4d}
-----------------------------------------------------------------------------------------------------

This report examines the evidence basis for various interventions in current use for controlling myopia progression in children, organized under the categories of optical, pharmacologic, environmental (behavioral), and surgical interventions (aimed at stabilizing highly myopic eyes). There is equivocal evidence concerning whether single-vision spectacles cause faster myopic progression than soft contact lenses, but any difference is likely to be clinically irrelevant. Undercorrection is still adopted as a myopia control strategy by some practitioners, yet some but not all clinical trials indicate this strategy has no clinically significant benefit in slowing myopia. Single-vision spectacle lenses designed to alter peripheral defocus had only a small treatment effect, of less than 14% reduction in myopia progression. The treatment effects on myopia progression of bifocal and progressive addition spectacles tend to be larger, although variable and questioned in terms of clinical significance in some cases (6%--51%). Overall, single-vision contact lenses, whether soft or rigid, seem to have little effect on myopia progression, in contrast to significant treatment effects with contact lenses that impose multifocality. Center-distance multifocal lenses have been used off-label successfully, demonstrating a sample size--weighted average of 38%, slowing both myopia progression and axial elongation, although these two assessment elements did not always correspond tightly. Orthokeratology has also proven to be effective in slowing axial length elongation, by between 30% to 55%.

Pharmacologic myopia control trials have principally used atropine, although other muscarinic antagonists such as M1 selective pirenzepine, ocular hypotensive agents including topical timolol (a nonselective β-adrenergic antagonist), and oral 7-methylxanthine, an adenosine antagonist, have also undergone trial. Although the reduction in myopia progression seems to be higher with 1% atropine (around 60%--80%), more recent atropine studies use much lower doses (e.g., 0.01%), with a reduced effect on refractive error retardation (around 45%) and no apparent effect of axial length compared to historical controls, but with fewer side effects and apparent rebound after discontinuation.

Time outdoors appears to be more effective in preventing incident myopia than slowing progression of existing myopia. However, the evidence for vitamin D levels being related to myopic control is weak. Seasonal trends in myopia progression have also been interpreted as indirect evidence of outdoor effects on myopia progression, based on observed faster myopia progression during the darker winter than the brighter summer months. In one study, every additional hour of outdoor time per week has been found to reduce the risk of developing myopia by 2%. In another study, the time children spend engaged in near work outside of school and time spent outdoor were not found to be related, as might be expected. Deployment of wearable technologies in place of questionnaires as study tools may help to resolve apparent inconsistencies and unresolved questions, including whether the quality of indoor lighting is important.

4.5 IMI -- Clinical Myopia Control Trials and Instrumentation Report[@i1552-5783-60-3-M1-b127] {#s4e}
----------------------------------------------------------------------------------------------

Clinical trials on myopia control conducted to date were reviewed to inform a consensus on best practice in the design of clinical trials to assess the effectiveness of treatments and the impact on patients. As myopia control interventions will be applied for multiple years throughout the time during which myopia is progressing, and treatment effects have been shown to often reduce after an initial period, it is important that clinical trials evaluate efficacy over a long period (3 years being the recommendation) to ensure continued efficacy beyond any initial treatment effect. Assessment of rebound should also be considered, with a minimum recommended period of 1 year due to seasonal effects. Typical inclusion criteria are cycloplegic spherical or spherical equivalent myopia of at least −0.75 D; astigmatism ≤ 1.00 D; anisometropia ≤ 1.50 D; ages 6 to 12 years; and 20/20 (0.0 logMAR) minimum visual acuity. Exclusion criteria typically are previous rigid contact lens wear; history of previous myopia control treatment; ocular pathology; binocular vision anomaly; medications that may affect pupil size, accommodation, or have an impact on ocular surface; and systemic disease that may affect vision, vision development, or the treatment modality. Appropriate control group selection depends on the intervention being studied, but often myopia control studies cannot be fully masked. Studies with no control group are unable to demonstrate treatment efficacy; as the rate of myopia progression decreases naturally with age and has seasonal variation, it is not possible to distinguish between naturally declining progression and reduced progression attributable to the treatment, without a simultaneously conducted control group. Randomization should be applied to treatment allocation, and stratification by key factors known to influence myopia progression (such as age and race/ethnicity) should be considered. Ocular health, including a slit lamp examination and baseline/periodic dilated fundus examination, along with standardized adverse event reporting, should also be embedded in the trial protocol. Binocular vision associations in myopia control treatments have also been found, so should be investigated at baseline and periodic intervals during the study. Other safety-related assessments include visual acuity and dysphotopsia. Finally, there is not a specific minimum percentage reduction in myopia progression that has been published for a treatment effect to be considered clinically meaningful; any such percentage reduction threshold could theoretically vary with multiple other factors, including duration of treatment, sample population, and study design considerations. Sample size estimations based on currently available measurement variability data are provided.

Outcome measures were classified as primary, secondary, and exploratory. Primary outcome measures are refractive error (ideally assessed objectively with autorefraction of the eye cyclopleged in optical intervention studies with 1% tropicamide) or axial length (ideally measured with noncontact interferometry) or both. Secondary outcome measures focus on patient-reported outcomes (usually assessed by questionnaire and can include the parent\'s/guardian\'s experience as well as the patient\'s) and treatment compliance (ideally in real time, such as with text messaging responses or wearable sensors connected to data loggers). Exploratory outcome measures are particularly useful in trying to understand the mechanism of action and associated factors. These include peripheral refraction (such as measured with autorefractors or wavefront aberrometers), accommodative changes (including accommodative lag and dynamics), ocular alignment, pupil size, outdoor activity/lighting levels, anterior and posterior segment structural changes (typically imaged with Scheimpflug imaging, optical coherence tomography, and retinal photography with a particular interest in choroidal thickness changes), and tissue biomechanics (of the sclera and cornea).

4.6 IMI -- Industry Guidelines and Ethical Considerations for Myopia Control Report[@i1552-5783-60-3-M1-b128] {#s4f}
-------------------------------------------------------------------------------------------------------------

The aim of this subcommittee was to discuss guidelines and ethical considerations associated with the development and prescription of treatments intended for myopia control. A critical review of published articles and guidance documents was undertaken, with a view to carefully consider the ethical standards associated with the investigation, development, registration, marketing, prescription, and use of myopia control treatments.

From an ethical standpoint, deciding whether to implement a myopia control strategy represents a classical medical risk versus benefit ratio. A principal motivation for slowing myopia progression is based on the premise that limiting myopia progression reduces risk of the development of vision-threatening disease in later life. However, conclusive evidence that this is the case is unlikely to be available for decades. Nonetheless, if this assumption is correct, then the benefits could be substantial, given the clear relationship between myopia-related ocular pathology and the degree of myopia. Thus, the risk-benefit analysis must take account of the outcomes arising from nonintervention in deciding if implementation of a myopia control strategy with an individual patient is warranted. Other factors to consider include the known improvements in quality-of-life issues arising from the use of corrective devices; adults with pathologic myopia and associated visual impairment report significant social and emotional impacts and reduced life satisfaction. Additional factors that must be accounted for in the decision to undertake myopia control include the regulatory status of the treatment being considered, availability of the treatment, access to appropriate eye care services, and pricing and convenience of the treatment, which are all potential barriers to accessing the myopia control treatment being considered.

These considerations place a burden of responsibility on the practitioner to be fully cognizant of the risks for the patient of developing different levels of myopia, the implications that progression to higher levels of myopia may have, the likely benefits of treatment, the side effects of treatment and other associated factors, so as to provide appropriate advice and care.

Researchers and clinicians often partner with companies to conduct myopia control studies. However, there is a risk for these partnerships to introduce bias, and practitioners should be aware of the importance of evaluating any real (or perceived) conflict of interest when recommending a management plan for myopia control. The interactions between researchers, practitioners, and manufacturers of myopia control treatments should meet the highest possible standards of integrity and transparency and must be declared in the reporting of the results obtained. Relationships between clinicians and patients should not be compromised by commercial or other interests that could subvert the principle that the interests of patients are of primary concern.

Most myopia control treatments are currently off-label in many countries. Most regulatory bodies do not restrict practitioners from discussing off-label treatment uses with their patients. However, given that patients and their families generally assume that a treatment prescribed by their clinician has been proven safe and effective and is supported by scientific evidence, it is recommended that practitioners ensure that a formal informed consent process is adopted, to ensure that the patient (and parents/guardians in some cases) is aware of the risks, benefits, and alternatives for any myopia control treatment discussed.

Regulatory bodies, manufacturers, academics, practitioners, and patients are all stakeholders and play an important role in ensuring the appropriate prescribing and success of myopia control treatments. Approval of a treatment by a regulatory body relies on the risk-benefit assessment and is informed by science, medicine, policy, and judgment, in accordance with applicable legal and regulatory standards. Manufacturers have a large part to play in the ethical decisions around the practitioner\'s prescribing of myopia control treatments by ensuring that the discussion of the efficacy of a treatment is appropriately reported and that the treatments are manufactured by using rigorous methods to ensure their quality. Academics have an important role in disseminating scientific information related to myopia control treatments, which is typically undertaken in the form of peer-reviewed journal articles, in addition to abstracts and presentations at major scientific conferences. Practitioners have a responsibility to care for their patients by recommending myopia control treatments using evidence-based practice. With a condition as multifactorial and individual as myopia, this means using published evidence along with clinical judgment to determine the best course of action for the young myopic patient. Finally, patients should be well informed about the nature of the product\'s marketing authorization status for the intended use and, in case of off-label/unlicensed treatments, that the risks associated with the treatment might be unknown. Such information should be provided in a neutral, balanced, and nonbiased way by the practitioner and be accompanied by easily accessible online and printed information.

Undertaking myopia control treatment in minors creates an ethical challenge for a wide variety of stakeholders. Regulatory bodies, manufacturers, academics, and clinicians all share an ethical responsibility to ensure that the products used for myopia control are safe and efficacious and that patients understand the benefits and potential risks of such products.

4.7 IMI -- Clinical Myopia Management Guidelines Report[@i1552-5783-60-3-M1-b129] {#s4g}
---------------------------------------------------------------------------------

This report draws on the evidence basis outlined principally in the IMI -- Interventions for Controlling Myopia Onset and Progression Report[@i1552-5783-60-3-M1-b88] for establishing clinical guidelines to inform the management of the progressing myopic patient. This includes risk factor identification from the assessment of refractive error, binocular visual function, parental refraction, and visual environment (such as educational intensity and time spent outdoors) at around ages 6 to 11 years; discussion of the prospect of developing myopia and the associated risks, along with treatment option efficacy, risks, and additional correction benefits with the parents/guardians and the patient in lay terms; setting realistic expectations; gaining informed consent; agreement of compliance and a follow-up schedule; and off-label considerations. Key baseline examination procedures include a detailed ocular and general health history (including parental refractive error, myopia onset, any previous correction/treatment, and time spent outdoors/doing detailed near work), subjective refraction (objective refraction following cycloplegia when indicated), visual acuity, binocular vision (principally vergence) and accommodation (particularly lag and amplitude) assessment, corneal topography (if considering orthokeratology), slit lamp biomicroscopy of the anterior eye (including signs of dry eye disease), intraocular pressure measurement (if considering pharmaceutical treatment), dilated fundus examination, and ideally noncontact axial length measurement. Exploratory tests that may be used clinically in future include uncorrected relative peripheral refraction, ocular aberrations, pupil size, subfoveal choroidal thickness, and wearable devices to track visual habits and the environment. Treatment strategies need to be agreed upon in conjunction with the patient and parents/guardians with aspects such as their risks/benefits, the patient\'s lifestyle, and ease of compliance taken into account. Myopia "calculators" can be useful to visualize the average potential outcome based on research studies, but it must be noted that projections are based on carefully selected subjects examined for between 2 and 5 years only. Owing to the inherent risks of any treatment (contact lens, pharmaceuticals), treatment is not generally advisable until the myopia is visually significant (−0.50 D to −0.75 D), and baseline refractive error will determine the availability and potential effectivity of treatment. Although undercorrecting myopia is still practiced in some countries, most robust studies show it to either have no effect or increase the rate of myopia progression, hence children should be encouraged to wear their myopic correction full time. Children should not be prevented from participating in near-work activity, but regular breaks and fixation changes from intense near work should be encouraged, along with sufficient time (8--15 hours/week) outdoors. Treatments are likely to be most effective at younger ages, when rapid progression is underway; the efficacy of some treatments may wane after the first 6 months to 2 years of treatment and the effects could rebound after cessation (particularly with higher-dose pharmaceuticals). The guidelines recommend 6 monthly follow-ups to monitor safety and efficacy of the myopia control treatment, performing the same tests as at baseline, but with cycloplegic refraction and dilated fundus examination conducted annually or on indication. The future research directions of myopia interventions and treatments are discussed, along with the provision of clinical references, resources, and recommendations for continuing professional education in this growing area of clinical practice.[](#i1552-5783-60-3-M1-t04){ref-type="table"}
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###### 

Consolidated Acronymn/Abbreviation List for IMI -- Reports

  **Abbreviation**   **Definition**
  ------------------ --------------------------------------------------------------------------------
  7-MX               7-Methylxanthine
  AC/A               Accommodative convergence to accommodation
  ACES               Anyang Childhood Eye Study
  Add                Bifocal addition
  ADTN               (+/−)-2-Amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene
  AF                 Retinal autofluorescence
  AL                 Axial length
  ALSPAC             Avon Longitudinal Study of Parents and Children
  ANSES              French Agency for Food, Environmental and Occupational Health & Safety
  APLP2              Amyloid-like protein-2
  AREDS              Age-Related Eye Disease Study
  ATOM               Atropine in the treatment of myopia
  atRA               All-trans-retinoic acid
  b                  Regression coefficient
  BAK                Benzalkonium chloride
  BF                 Bifocal
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